Reports and guidance documents; availability, etc.: Source plasma donors participating in plasmapheresis and immunization programs; informed consent recommendations, 34260 [E7-11997]

Agencies

• Food and Drug Administration

[Federal Register: June 21, 2007 (Volume 72, Number 119)]
[Notices]
[Page 34260]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr21jn07-49]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2006D-0108]


Guidance for Industry: Informed Consent Recommendations for
Source Plasma Donors Participating in Plasmapheresis and Immunization
Programs; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a document entitled ``Guidance for Industry: Informed
Consent Recommendations for Source Plasma Donors Participating in
Plasmapheresis and Immunization Programs,'' dated June 2007. The
guidance document further explains the requirements and recommendations
for the informed consent of donors of Source Plasma in plasmapheresis
and immunization programs. The guidance document is designed to assist
blood establishments that are planning to apply for licensure or
revising their existing informed consent procedures. The guidance
announced in this notice finalizes the draft guidance of the same title
dated April 2006. This guidance supersedes the draft guidance document
entitled ``Draft Reviewer's Guide: Informed Consent for Plasmapheresis/
Immunization,'' dated October 1995.

DATES: Submit written or electronic comments on agency guidances at any
time.

ADDRESSES: Submit written requests for single copies of the guidance to
the Office of Communication, Training, and Manufacturers Assistance
(HFM-40), Center for Biologics Evaluation and Research (CBER), Food and
Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD
20852-1448. Send one self-addressed adhesive label to assist the office
in processing your requests. The guidance may also be obtained by mail
by calling CBER at 1-800-835-4709 or 301-827-1800. See the
SUPPLEMENTARY INFORMATION section for electronic access to the guidance
document.
    Submit written comments on the guidance to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
rm. 1061, Rockville, MD 20852. Submit electronic comments to https://www.fda.gov/dockets/ecomments
.


FOR FURTHER INFORMATION CONTACT: Joseph L. Okrasinski Jr., Center for
Biologics Evaluation and Research (HFM-17), Food and Drug
Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852-
1448, 301-827-6210.

SUPPLEMENTARY INFORMATION:

I. Background

    FDA is announcing the availability of a document entitled
``Guidance for Industry: Informed Consent Recommendations for Source
Plasma Donors Participating in Plasmapheresis and Immunization
Programs,'' dated June 2007. The guidance further explains the
requirements in Sec.  640.61 (21 CFR 640.61) and makes recommendations
for the informed consent of donors of Source Plasma in plasmapheresis
and immunization programs. The guidance discusses informed consent
issues applicable to all Source Plasma donors, including describing the
hazards of the procedures, the importance of affording the donor an
opportunity to ask questions, and the potential consequences for the
donor if the results of tests for communicable disease agents are
reactive, positive, or outside of normal limits. The guidance also
discusses additional informed consent issues for a donor who is
participating in an immunization program. The information in the
guidance will assist those establishments applying for licensure as
well as those establishments that are revising their existing informed
consent procedures.
    In the Federal Register of Thursday, April 27, 2006 (71 FR 24857),
FDA announced the availability of the draft guidance of the same title
dated April 2006. FDA received several comments on the draft guidance,
and those comments were considered as the guidance was finalized. The
guidance announced in this notice finalizes the draft guidance dated
April 2006. This guidance will supersede the draft guidance document
entitled ``Draft Reviewer's Guide: Informed Consent for Plasmapheresis/
Immunization,'' dated October 1995.
    The guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). The guidance represents FDA's
current thinking on this topic. It does not create or confer any rights
for or on any person and does not operate to bind FDA or the public. An
alternative approach may be used if such approach satisfies the
requirements of the applicable statutes and regulations.

II. Paperwork Reduction Act of 1995

    This guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in Sec.  640.61 and 21 CFR 640.66 have been
approved under OMB control number 0910-0116.

III. Comments

    Interested persons may, at any time, submit to the Division of
Dockets Management (see ADDRESSES) written or electronic comments
regarding the guidance. Submit a single copy of electronic comments or
two paper copies of any mailed comments, except that individuals may
submit one paper copy. Comments are to be identified with the docket
number found in brackets in the heading of this document. A copy of the
guidance and received comments are available for public examination in
the Division of Dockets Management between 9 a.m. and 4 p.m., Monday
through Friday.

IV. Electronic Access

    Persons with access to the Internet may obtain the guidance at
either https://www.fda.gov/cber/guidelines.htm or https://www.fda.gov/ohrms/dockets/default
.htm.

    Dated: June 13, 2007.
Randall W. Lutter,
Acting Deputy Commissioner for Policy.
[FR Doc. E7-11997 Filed 6-20-07; 8:45 am]

BILLING CODE 4160-01-S